Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with DLBCL
and relapse after complete remission or disease progression after partial remission who are ineligible for autologous stem cell transplantation
and relapse after complete remission or disease progression after partial remission following autologous stem cell transplantation.
Clareo Health | Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
